Trial Profile

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Cladribine (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Mitoxantrone (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate sodium (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
Focus Therapeutic Use

20 Feb 2025 Planned End Date changed from 31 Dec 2027 to 17 Mar 2027.
20 Feb 2025 Planned primary completion date changed from 31 Dec 2025 to 28 Feb 2027.
09 Jan 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com